2023+意大利全国共识：难治性抑郁症的临床管理（英文版）.pdf

《2023+意大利全国共识：难治性抑郁症的临床管理（英文版）.pdf》由会员分享，可在线阅读，更多相关《2023+意大利全国共识：难治性抑郁症的临床管理（英文版）.pdf（11页珍藏版）》请在周易易学书店|道易五术书社上搜索。

1、Mainaetal.Annals of General Psychiatry https:/doi.org/10.1186/s12991-023-00478-7RESEARCHOpen Access The Author(s)2023.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,which permits use,sharing,adaptation,distribution and reproduction in any medium o

2、r format,as long as you give appropriate credit to the original author(s)and the source,provide a link to the Creative Commons licence,and indicate if changes were made.The images or other third party material in this article are included in the articles Creative Commons licence,unless indicated oth

3、erwise in a credit line to the material.If material is not included in the articles Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use,you will need to obtain permission directly from the copyright holder.To view a copy of this licenc

4、e,visit http:/cr eat iv eco mmons.or g/licen ses/b y/4.0/.The Creative Commons Public Domain Dedication waiver(http:/cr eat iv eco mmons.or g/publi cdoma in/z er o/1.0/)applies to the data made available in this article,unless otherwise stated in a credit line to the data.Annals of General Psychiatr

5、yNationwide consensus ontheclinical management oftreatment-resistant depression inItaly:aDelphi panelGiuseppe Maina1,2,Marina Adami3,Giuseppe Ascione3,Emi Bondi4,Domenico De Berardis5,Dario Delmonte3,Silvia Maezzoli3,Giovanni Martinotti6,Alessandra Nivoli7,Elena Ottavianelli8*,the Delphi Panel Colla

6、boration Group and Andrea Fagiolini9 Abstract Background Treatment-resistant depression(TRD)is dened by the European Medicines Agency as a lack of clini-cally meaningful improvement after treatment,with at least two dierent antidepressants.Individual,familiar,and socio-economic burden of TRD is huge

7、.Given the lack of clear guidelines,the large variability of TRD approaches across dierent countries and the availability of new medications to meet the need of eective and rapid acting therapeutic strategies,it is important to understand the consensus regarding the clinical characteristics and trea

8、tment pathways of patients with TRD in Italian routine clinical practice,particularly in view of the recent availability of esketa-mine nasal spray.Methods A Delphi questionnaire with 17 statements(with a 7 points Likert scale for agreement)was administered via a customized web-based platform to Ita

9、lian psychiatrists with at least 5 years of experience and specic expertise in the eld of depression.In the second-round physicians were asked to answer the same statements considering the interquartile range of each question as an index of their colleagues responses.Stata 16.1 software was used for

10、 the analyses.Results Sixty panellists,representative of the Italian territory,answered the questionnaire at the rst round.For 8/17 statements more than 75%of panellists reached agreement and a high consensus as they assigned similar scores;for 4 statements the panellists assigned similar scores but

11、 in the middle of the Likert scale showing a moderate agreement with the statement,while for 5 statements there was indecision in the agreement and low consensus with the statement.Conclusions This Delphi Panel showed that there is a wide heterogeneity in Italy in the management of TRD patients,and

12、a compelling need of standardised strategies and treatments specically approved for TRD.A high level of consensus and agreement was obtained about the importance of adding lithium and/or antipsychotics as aug-mentation therapies and in the meantime about the need for long-term maintenance therapy.A

13、high level of con-sensus and agreement was equally reached for the identication of esketamine nasal spray as the best option for TRD patients and for the possibility to administrate without diculties esketamine in a community outpatient setting,highlighting the benet of an appropriate educational su

14、pport for patients.*Correspondence:Elena Ottavianellielena.ottavianellifullcro.orgFull list of author information is available at the end of the articlePage 2 of 11 Mainaetal.Annals of General Psychiatry Keywords Treatment-resistant depression,Major depressive disorder,Antidepressants,Consensus stat

15、ement,Customized treatment,EsketamineBackgrounde primary goal of treating depression is to achieve complete resolution of symptoms,but approximately 30%of patients with major depressive disorder(MDD)do not respond adequately to treatment 1,2.Non-response to medication is common and can persist after

16、 multi-ple attempts with dierent medications 2.e suc-cess rate of treatment decreases with each subsequent trial,as shown in the Sequenced Treatment Alternatives to Relieve Depression(STAR-D)trial 1.Treatment-resistant depression(TRD)is dened by the European Medicines Agency(EMA)as a lack of clinica

17、lly mean-ingful improvement after treatment with at least two dierent antidepressants 3.TRD is a complex condi-tion inuenced by genetic,clinical and environmental factors,as well as comorbidities and psychosocial fac-tors 4.Patients with TRD experience a higher burden of illness compared to responde

18、rs,including more severe symptoms,greater disability,and reduced quality of life 2,5.e economic burden of TRD is also signicant,with higher direct and indirect costs compared to non-treatment-resistant depression 6.Current management of TRD is challenging due to the lack of evidence-based guidelines

19、 or a consensus strategy in Europe,leading to variation in treatment choices 7.Pharmacological options,that include selective serotonin reuptake inhibi-tors(SSRI),serotoninnorepinephrine reuptake inhibi-tors(SNRI),tricyclic antidepressants(TCA),monoamine oxidase inhibitors(MAOIs),and atypical antide

20、pressants and non-pharmacological treatments(neurostimulation,psychotherapeutic interventions)could be used,alone or in combination,with dierent strategies,such as dose escalation,medication switching,combination therapy,and augmentation/additional therapy.e everyday Ital-ian clinical practice is no

21、t dierent from the European context;in Italy it can be documented,on the one hand the frequent use of SSRI,SNRI and augmentation strate-gies,and on the other hand the rare utilization of psycho-social approaches 5.However,in real-world practice,treatment response rates are low.A recent observational

22、 study on TRD in Europe conrmed that TRD patients have a poor chance of achieving remission at both 6 and 12months;more-over,the study found that patients who had achieved remission at 6months were then unable to maintain it for a long time 7.Despite low remission rate,TRD patients often remain on t

23、he same pharmacological treatment for extended periods of time 7,8.ere is a need for additional therapeutic strategies for TRD that are rapid acting and have proven ecacy in this population 4,9,10.Ketamine and its S-enantiomer,esketamine,have shown promise in targeting the glutamate pathway and rest

24、oring synaptic connections in the brain to improve mood symptoms 11,12.Esketamine nasal spray,devel-oped and approved specically for TRD,provides an additional treatment option with rapid onset of action and demonstrated ecacy compared with other well-established pharmacological strategy such as aug

25、men-tation with quetiapine XR 13.Few adverse events are reported with esketamine(the most common are tran-sient dissociative symptoms,nausea,dizziness)14 and the safety concerns can be managed by administering esketamine under healthcare professional supervision in accordance with best practices 15.

26、Cost-utility analysis suggests that esketamine may be a cost-eective option for the treatment of TRD 16.Future developments in pharmacological treatments of TRD are testing ketamine derivatives or other glutamatergic agents.In addition,GABAergic agents(e.g.,zuranolone),opioid receptor and voltage-ga

27、ted ion channels modulators,orexin antago-nists,but also anti-inammatory,as well as thyroid hor-mones are under investigation in TRD 15.Given the lack of clear guidelines and the availabil-ity of new medications,it is important to understand the consensus regarding the clinical characteristics and t

28、reatment pathways for patients with MDD and TRD in routine clinical practice,particularly regarding esketa-mine nasal spray.Methodse Delphi technique,developed in 1962 17,derives the name from the Delphic oracles skills of interpretation and foresight;it is a process used to achieve a consensus conc

29、erning real-world knowledge from experts about certain areas.Delphi is a well-established methodology used in the scientic eld 18,19.e Delphi process traditionally begins with a small group of experts prepar-ing a questionnaire based upon an extensive review of the literature;this questionnaire is u

30、sed as the instrument of the survey.Each Delphi participant is asked to review and rate the summarized statements so that areas of con-sensus and non-consensus can be identied.Each Delphi participant receives,in subsequent rounds,a question-naire that includes the statements and ratings(from the pre

31、vious round)and are asked to re-evaluate their initial judgment.Page 3 of 11 Mainaetal.Annals of General Psychiatry Expert board andconsensus panelIn September 2022,a board of 6 experts,based on their documented expertise in the TRD eld,met to review the current landscape of the disease and identify

32、 key top-ics for clinical management.All members of the expert board disclosed potential conicts of interest.At the end of the topic selection process,replies and redundancies were eliminated and 17 statements were generated for testing across a wider audience using the Delphi questionnaire.e statem

33、ents can be grouped as follows:Clinical characteristics and diagnosis of patients with TRD(statements:1,2,3)Treatment journey and organizational implications(statements:4,5,6,13,16,17)Antidepressant treatment in routine clinical practice(statements 7,8,9,10,11,12,14,15).e panellists have been identi

34、ed by the experts board according to the following criteria,decided during the rst meeting and were asked for volunteer participation:specialized in psychiatry,with specic expertise in the eld of depression(at least 100 patients/year)and direct or indirect experience with esketamine nasal spray;year

35、s of experience(at least 5 including specializa-tion);working in the Italian National Health Service(pub-lic service,outpatient/territorial setting,University in agreement with NHS);representative of the Italian territory.Questionnaire andstatistical analysese Delphi questionnaire was administered v

36、ia a web-based system.e platform used for the data collection,called NPCdata_survey DE9 Version 1.0 is dedicated to the management of Delphi conferences.e system has been validated according to GAMP V guidelines and resides in a protected area on ARUBA servers.Data integrity security is guaranteed b

37、y ARUBA back-up sys-tems and Fullcros internal procedures.e access to the system was done through LogIn.Each user was assigned a unique code and link to the system.is method granted anonymity and absence of inter-ference among the panellists.e link to the web was sent by e-mail with a maximum of one

38、 reminder.e denitions for consensus and non-consensus were decided a priori.A Likert scale was used(1=no agree-ment to 7=maximum agreement)to evaluate the degree of agreement with each of the statements proposed in the questionnaire.In the rst round,the user logged into the system and provided a sco

39、re to all the statements(mandatory responses).After saving,the access is removed to pre-vent any change to the answers provided.At the end of the rst round(October 27Novem-ber 15,2022),the median value and the 25th and 75th percentiles(75th p25th p,interquartile range)of each statement were calculat

40、ed.In the second round(21 November19 December 2022),the system presented,for each statement,the answers provided by the user in the rst round and the interquartile ranges calculated across the entire data-base(which represents the range in which 50%of the answers fell)as an index of their colleagues

41、 responses.ose who answered outside the interquartile range(IQR)in the second round were asked by the system to give a reason for their response.In the absence of this information the system does not save the session.At the end of the second round,the median value and the 25th and 75th percentiles o

42、f each statement and IQR were calculated again.e results of the rst and second rounds and the motivations of those who had answered outside the interquartile range,were discussed by the expert board at the“verication meeting”(January 2023).After dis-cussing and commenting on the results of each of t

43、he 17 statements,the expert board members formulated the counter-motivations.Since all 17 statements reached agreement and consensus;it was decided not to proceed with the third round.e ow chart of the analysis is presented in Fig.1.e statements were ranked based on the 25th per-centile,75th percent

44、ile and the interquartile range(IQR)(Fig.2):Agreement and consensus with the statement:Ar-mations that have the 25th percentile 4 and IQR 2 but dierent from 4 to 4 belong to this group.Agreement and low consensus with the statement:ose statements that have the 25th percentile 4 and IQR 3 belong to t

45、his group.Indecision in the evaluation and consensus with the statement:ose statements that have the 25th per-centile 4 and IQR 44 or 25th percentile 4 and IQR 2 belong to this group.Indecision in the evaluation and low consensus with the statement:ose statements that have the 25th percentile 4 and

46、IQR 3.Disagree and consensus with the statement:ose statements that have the 25th percentile 4,75th per-centile 4 and IQR 2 belong to this group.Page 4 of 11 Mainaetal.Annals of General Psychiatry Disagree and low consensus with the statement:ose statements that have the 25th percentile 4,75th perce

47、ntile 4 and IQR 3 belong to this group.Median and 25th percentile,75th percentile and IQR were reported for each statement and round(Additional le1).Stata 16.1 software was used for the analyses.ResultsParticipantsSixty panellists answered the questionnaire at the rst round,and 58 at the second roun

48、d.With regard to the geographic distribution,the panel was well representative of the Italian situation(33%North,20%Centre,47%South and Islands).Among the 60 participants 21 worked in universities,39 in public structures as Department of Mental Health,organized in day-care Mental Health Centers or H

49、ospital Diagnosis and Treatment of Psychiatric Services.e overall result of the 17 statements is summarized in Table1 and displayed in graphical form(level of agree-ment/disagreement distribution by box plot and bar graph)in Fig.3.For 8 among the 17 statements of the Delphi more than 75%of panellist

50、s assigned a score of 4 or more reach-ing agreement(25th percentile 4).ese statements also reached a high consensus(IQR 2)as the panellists assigned similar scores.e 8 statements are:8.When treating a depressed patient who has failed to respond to two antidepressants,I do tend to add lithium rst.For